Financial reports
Current reports
6-K
Availability of the preparatory documents
7 May 24
6-K
Abivax reports 2023 financial results and operational update
2 Apr 24
6-K
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
2 Feb 24
6-K
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
22 Jan 24
Registration and prospectus
424B4
Prospectus supplement with pricing info
23 Oct 23
FWP
Free writing prospectus
20 Oct 23
8-A12B
Registration of securities on exchange
18 Oct 23
F-1/A
Registration statement (foreign) (amended)
18 Oct 23
F-1/A
Registration statement (foreign) (amended)
16 Oct 23
F-6
Registration for ADRs (foreign)
3 Oct 23
F-1
Registration statement (foreign)
29 Sep 23
DRS/A
Draft registration statement (amended)
8 Sep 23
DRSLTR
Correspondence regarding draft registration statement
8 Sep 23
DRS/A
Draft registration statement (amended)
28 Jul 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
20 Oct 23
EFFECT
Notice of effectiveness
20 Oct 23
SEC STAFF LETTER
SEC staff letter
20 Oct 23
CERT
Certification of approval for exchange listing
19 Oct 23
CORRESP
Correspondence with SEC
18 Oct 23
CORRESP
Correspondence with SEC
18 Oct 23
CORRESP
Correspondence with SEC
18 Oct 23
UPLOAD
Letter from SEC
17 Oct 23
CORRESP
Correspondence with SEC
16 Oct 23
UPLOAD
Letter from SEC
5 Oct 23